The C-Terminal Half of SARS-CoV-2 Nucleocapsid Protein, Industrially Produced in Plants, Is Valid as Antigen in COVID-19 Serological Tests.

Background: The fight against the current coronavirus disease 2019 (COVID-19) pandemic has created a huge demand of biotechnological, pharmaceutical, research and sanitary materials at unprecedented scales. One of the most urgent demands affects the diagnostic tests. The growing need for rapid and accurate laboratory diagnostic tests requires the development of biotechnological processes aimed at producing reagents able to cope with this demand in a scalable, cost-effective manner, with rapid turnaround times.

Potential Application of Plant-derived Bioengineered Human VEGF for Tissue Regeneration.

The design and development of novel biological drugs are among the most exciting new areas of biotechnology which are gaining the attention of scientists. In the last few decades several fabrication processes have been proposed and developed for the production of recombinant growth factors. However, traditional production processes have several limitations in terms of scale- up, cost-efficiency and purity grade of the proteins.